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Genome-scale study reveals reduced metabolic
adaptability in patients with non-alcoholic fatty
liver disease
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Amalia Gastaldelli8, Hannele Yki-Ja¨rvinen4,5, Eytan Ruppin3,9 & Matej Oresˇicˇ1,2,10
Non-alcoholic fatty liver disease (NAFLD) is a major risk factor leading to chronic liver
disease and type 2 diabetes. Here we chart liver metabolic activity and functionality in NAFLD
by integrating global transcriptomic data, from human liver biopsies, and metabolic ﬂux data,
measured across the human splanchnic vascular bed, within a genome-scale model of
human metabolism. We show that an increased amount of liver fat induces mitochondrial
metabolism, lipolysis, glyceroneogenesis and a switch from lactate to glycerol as substrate for
gluconeogenesis, indicating an intricate balance of exacerbated opposite metabolic processes
in glycemic regulation. These changes were associated with reduced metabolic adaptability
on a network level in the sense that liver fat accumulation puts increasing demands on the
liver to adaptively regulate metabolic responses to maintain basic liver functions. We propose
that failure to meet excessive metabolic challenges coupled with reduced metabolic
adaptability may lead to a vicious pathogenic cycle leading to the co-morbidities of NAFLD.
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T
he prevalence of non-alcoholic fatty liver disease (NAFLD)
in US adults doubled from 5.51 to 11.01% between 1988
and 2008 and may soon reach epidemic proportions if the
current rates of obesity and diabetes continue to escalate1.
NAFLD is a major component of the metabolic syndrome2–4, but
despite its importance it is yet poorly understood. We have
previously shown that fatty liver synthesizes excess triglycerides
with low carbon number and double bond content5, indicative of
increased de novo hepatic lipogenesis5,6. Recent research also
implicates activation of liver mitochondrial pathways, de-novo
lipogenesis and gluconeogenesis (GNG) contributing to the
development of NAFLD7.
As it is technically demanding and highly invasive, only
a few studies have investigated the human splanchnic
metabolism of metabolites such as amino acids, free fatty
acids (FFAs) and ketone bodies in vivo8,9. The main limitation
of such early studies was a poor coverage of the metabolites
associated with liver functions, because of the limitations in
sensitivity or selectivity of the analytical methodologies available
at that time. Metabolomics platforms that afford comprehensive
coverage of polar metabolites and molecular lipids are now
available.
Here we aim to characterize these essential metabolic pathways
of the human liver on a genome scale. We harness genome-scale
metabolic modelling (GSMM) to meet the challenges introduced
by high-throughput and data-rich biology. GSMM has been
shown to provide an appropriate context for analysing high-
dimensional ‘omics’ data sets and elucidate the genotype-to-
phenotype relationship10–14. Accounting for thermodynamic and
stoichiometric constraints, GSMM captures metabolic
phenotypes under diverse physiological and genetic
conditions13–15. Algorithmic approaches have leveraged GSMM
as a mechanistic scaffold for drug discovery16 and biomarker
identiﬁcation17. GSMM was recently applied to study NAFLD
and non-alcoholic steatohepatitis (NASH)18. In this study,
a GSMM of hepatocytes was constructed and utilized to
analyse gene expression proﬁles of NAFLD patients. Blood
concentrations of chondroitin and heparan sulphates were found
suitable for diagnosing NASH and staging NAFLD. Taken
together, these recent methodological developments now lay the
basis for integrated experimental-computational studies that
could broaden our understanding of the metabolic processes
associated with the normal and pathological human liver.
With the aim to analyse liver metabolism at the genome scale
in response to NAFLD development, herein we obtain
transcriptomics in human liver biopsies from subjects with
NAFLD and controls, and—for the ﬁrst time—comprehensively
characterize the metabolic ﬂuxes across the splanchnic bed in
human fatty liver. The ﬂuxes and gene expression data are
integrated with a genome-scale model of human metabolism10,19
to chart liver metabolic activity in NAFLD on a genome scale
aiming to identify its distinctive features (Fig. 1).
Results
Gene expression-based analysis of liver metabolic functionality.
Gene expression was measured in the human liver of eight
subjects with extreme steatosis diagnosed with NAFLD (liver fat
% range 20–80%), and eight healthy subjects with low liver fat
content (liver fat % range 0–10%; Supplementary Table 1). There
was no signiﬁcant difference between the groups in age, gender
and PNPLA3 genotype at single-nucleotide polymorphism
rs738409. In the high liver fat group, there were two patients who
had mild ﬁbrosis but no patients had impaired hepatic function.
Subjects with high liver fat content had slightly but not
signiﬁcantly higher fasting glucose and HbA1c concentrations
than subjects with low liver fat content. They also had
signiﬁcantly higher liver enzyme concentrations.
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Figure 1 | Design of the study. Genome-scale human metabolic model is integrated with the liver gene expression proﬁle (human liver biopsies from
subjects with NAFLD and controls) and the splanchnic ﬂux (metabolomics of human serum from hepatic vein and artery from subjects with NAFLD) data
by using GSMM. The GSMM analysis provides liver functionality scores, reaction activity and pathway enrichment in the context of NAFLD.FVA, ﬂux
variability analysis; iMAT, Integrative Metabolic Analysis Tool; MPA, metabolic phenotypic analysis; QP, quadratic programming.
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The metabolic functionality of each of these patients was
evaluated by inferring their capacity to carry out various liver
metabolic functions, as deﬁned by Gille et al.20. To this end, the
gene expression proﬁles were integrated with a GSMM and
transformed into metabolic functionality proﬁles21. The
metabolic model used—Homo sapiens Recon 1—accounts for
the functions of 1,496 open reading frames, 2,004 proteins, 2,766
metabolites and 3,311 metabolic and transport reactions22.
The metabolic functionality proﬁle of a patient was generated
in two complementary ways. First, we estimated the activity level
of different metabolic functions under the constraint to maintain
an optimal ﬁt to the gene expression, by applying the integrative
Metabolic Analysis Tool (iMAT)19,23. Second, we applied another
GSMM approach for integrating ‘omics’ data termed metabolic
phenotypic analysis (MPA)24. Given the gene expression proﬁle,
MPA assigns each metabolic function an adaptability score.
A high adaptability score indicates that the function studied can
be carried out with relatively little deviation from the given
expression state; a low adaptability score denotes that in
order to perform that function the cells must undergo
considerable transcriptional changes or post-transcriptional
regulation to enable the desired ﬂux rerouting to be carried on
(see Methods). The metabolic proﬁles obtained by iMAT and
MPA are hence complementary representations of the metabolic
state: iMAT infers the ﬂux activity of the function at the time the
gene expression was taken, whereas MPA aims to deduce the
underlying metabolic adaptability at the network level.
The GSMM functionality analysis described above showed that
the NAFLD group was characterized by decreased activity of
GNG from lactate as compared with the control group (Fig. 2a),
that is, in NAFLD patients less lactate is converted into glucose
via GNG. According to the metabolic adaptability scores, the low
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Figure 2 | GSMM analysis reveals reduced metabolic adaptability in NAFLD. Median functionality scores (y axis) obtained in the high (red) and low
(blue) fat groups according to: (a) iMAT and (b) metabolic adaptability analysis (MPA). The functions are ordered according to their P-values (Wilcoxon
signed-ranksum test), from largest to smallest, such that the ones that are on the right side of the dashed line obtained P-values that are less than 0.1.
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liver fat group consistently exhibited higher metabolic
adaptability throughout the different metabolic functions versus
the NAFLD group (Fig. 2b). Speciﬁcally, the NAFLD group had
defective adaptability of ureagenesis and metabolic functions
related to GNG (Wilcoxon signed rank sum test P-valueso0.05).
A genome-scale view of splanchnic ﬂuxes in NAFLD. Next, we
compared the GSMM predictions from the transcriptomics study
with metabolomics data measured across human splanchnic
vascular bed in an independent study. Nine subjects with NAFLD
underwent hepatic venous catheterization in the fasting (basal)
state and during euglycemic hyperinsulinemia5 (Supplementary
Table 2). Global proﬁling of small polar metabolites25 and
targeted proﬁling of bile acids26 were applied to study the ﬂuxes
and ratios of the metabolites in NAFLD subjects with varying
levels of liver fat content (Supplementary Table 3). Although
these measurements provide an opportunity to characterize
metabolism in the human liver, they are limited to a small
number of ﬂuxes measured at speciﬁc uptake and secretion
reactions. Nonetheless, these observed ﬂuxes constrain
considerably the ﬂux distribution over the rest—unobserved—
liver metabolic reactions.
To uncover the latter, we employed an iMAT GSMM analysis
of the human metabolic model to predict the most likely ﬂux
activity state induced upon the network given the ﬂux data
measured (Supplementary Table 4). Reassuringly, the activity
state inferred by the genome-scale model was consistent with the
observed ﬂuxes in a statistically signiﬁcant manner (empirical
P-value of 0.002 versus its ﬁt to randomly generated ﬂux data;
see Methods). Furthermore, a standard leave-one-out cross-
validation procedure demonstrated that the model correctly
predicts the ﬂux of a measured reaction when other ﬂux
measurements are provided (Spearman correlation P-value of
1.34 10 11). Thus, using this analysis of the measured—small-
scale—ﬂux data, we were able to reliably infer the metabolic
activity at the level of reactions, and at the level of metabolic
pathways and functions, on a genome scale.
To test whether the GSMM analysis provides a reliable
platform to compare the metabolic state based on different data
sources, we also computed the metabolic functionality scores,
based on the ﬂux measurements and gene expression, and utilized
them as classiﬁcation features. According to these features, the
patients were classiﬁed as having high or low liver fat amount via
Support Vector Machine (SVM)27. First, only the patients whose
gene expression was measured were classiﬁed. The classiﬁer that
exploits the metabolic functionality scores as features obtained a
signiﬁcantly high mean area under the curves (AUC) of 0.857
(empirical P-value of 0.06). It signiﬁcantly improves upon the
classiﬁer that utilizes the raw gene expression as features (mean
AUC of 0.774; empirical P-value of 0.178). Classifying all patients
according to the metabolic functionality scores also obtained a
signiﬁcantly high AUC of 0.79 (empirical P-value of 0.029).
Furthermore, when training the classiﬁer based on the metabolic
functionality scores inferred from the ﬂux measurements and
testing it based on those inferred from the gene expression, the
obtained AUC is 0.792 (empirical P-value of 0.065). These results
demonstrate the potency and validity of GSMM as a unifying
representation. By deducing the metabolic phenotype it enables
one to bridge across different measurement types as gene
expression and ﬂux rates.
GSMM analysis of the splanchnic gradients showed that, as
expected, the basal state is signiﬁcantly less metabolically active
compared with the euglycemic hyperinsulinamic state (Wilcoxon
ranksum test P-value of 3.557 10 4; Supplementary Table 4).
Lactate and intermediates of GNG as pyruvate and citrate were
taken up by the liver (Supplementary Table 3). In addition,
glutamic acid, several sugar derivatives and hydroxy-acids as
ketoacids and a-hydroxybutyric acid were produced by the liver.
Most of the bile acids and amino acids, including alanine and
methionine, were taken up by the liver. Notably, serine, which
was proposed to be decreased in the liver of NASH patients18, was
taken up by the liver.
As expected, the anabolic state induced by the euglycemic
hyperinsulinamic clamp triggered major changes in the metabolic
ﬂuxes (Fig. 3 and Supplementary Tables 4–5). As shown in Fig. 3,
fatty acids, asparagine, glutamate, cysteine, triglycerides and
glucose were produced by the liver in both basal state and after
insulin infusion. The insulin infusion also induced the biosynth-
esis of bile acids, nucleotides and glycogen, consistent with
anabolic effects of insulin. Insulin administration decreased the
plasma concentration of branched chain amino acids.
Liver fat has a major effect on liver metabolic pathways.
Examining the experimental ﬂux measurements directly from
measured metabolite concentration data, a large number of key
metabolite ﬂuxes were strongly associated with the amount of
liver fat, particularly in the basal state (Supplementary Table 6).
Also the arterial concentrations of fuel substrates were upregu-
lated (1.4- to 1.9-fold) in those patients with very high liver fat
accumulation. Speciﬁcally, lactic acid (Po0.001; two-sided t-test),
pyruvic acid (P¼ 0.017), FFAs (P¼ 0.0012), alanine (Po0.001)
and b-hydroxybutyrate (P¼ 0.0089) were increased in patients
with increased liver fat content. Splanchnic ﬂuxes of lactic acid
(Spearman correlation R¼  0.99, Po0.001) and pyruvic acid
(R¼  0.997, Po0.001) were inversely correlated with liver fat
amount in the basal state. b-Hydroxybutyrate was produced
across the splanchnic bed in all patients.
Patients with higher liver fat had lower measured uptake of
fatty acids and glycerol as compared with the patients with lower
liver fat. On the other hand, the uptake of amino acids,
particularly alanine (Po0.001), was higher in patients with
higher liver fat. The insulin administration caused clear changes
in metabolic ﬂuxes of the patients with relatively low amount of
liver fat. In contrast, patients with very high liver fat did not
respond to insulin administration as there was hardly any change
in metabolite ﬂuxes associated with glycolysis, lipolysis or
ketogenesis.
Flux-based GSMM analysis also conﬁrmed that three speciﬁc
processes: (i) increased activity of pathways leading to GNG and
glyceroneogenesis, (ii) trichloroacetic acid (TCA) cycle and (iii)
de novo lipogenesis were signiﬁcantly increased in the patients
with high amount of liver fat. In the basal state, the maximal
ﬂuxes of 39 reactions were signiﬁcantly positively correlated
(empirical and Spearman correlation P-valueo0.05; with false
discovery rate correction for multiple-hypotheses) with the
amount of fat (Supplementary Table 7). These reactions were
highly enriched with reactions of triglyceride synthesis and
lipogenic processes (hyper-geometric P-value of 3.9 10 4).
Type 2 diabetes leads to increased GNG from lactate/pyruvate.
Diabetes worsens the situation, as these subjects not only have
more liver fat than healthy subjects but also have increased fasting
glucose production and GNG, and impaired suppression of
glucose production, GNG and peripheral lipolysis during insulin
administration. We examined previously unreported data on
relative contribution of different sources to GNG from an earlier
study of diabetic and nondiabetic obese patients28. In diabetic
patients, lactate/pyruvate and amino acids contribute to GNG
more than glycerol. However, it cannot be excluded that the
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glyceroneogenic pathway is increased and contributes to excess
triglyceride synthesis (Fig. 4).
Discussion
In this study, we show that the liver adaptively regulates
metabolic responses to maintain its basic functions. We also
show that NAFLD is associated with increased mitochondrial
metabolism, lipolysis, glyceroneogenesis and a switch from lactate
to glycerol as substrate for GNG. Tight balance between the
increased glyceroneogenesis and GNG from glycerol may help
maintain the glycemic control in nondiabetic subjects (Fig. 5), but
at a cost of lower adaptability of the global metabolic network as
observed by GSMM analysis. This balance clearly breaks down in
type 2 diabetic subjects, where the contribution to GNG from
lactate/pyruvate is markedly increased.
The increased utilization of glycerol as substrate for GNG may
facilitate the development of metabolic co-morbidities of NAFLD
as glycerol is the only gluconeogenic substrate that imports new
carbons to the glucose pool and might therefore contribute to
deterioration of glycemic control29,30. However, glycerol could
also be used for triglyceride synthesis as the liver is one of
the few organs that contains glycerokinase. The increased
glyceroneogenesis, which may contribute to glycemic control in
nondiabetic subjects by reducing the contribution of lactate to
GNG (Fig. 5), may therefore come at a cost of increased
triglyceride synthesis31 and increased GNG from glycerol.
Our key ﬁndings corroborate several of the earlier ﬁndings.
Speciﬁcally, the substrate concentrations as well as ﬂuxes of
amino acids, ketone bodies and pyruvate are consistent with
earlier studies describing splanchnic ﬂuxes in obesity and various
liver diseases8,9. Among them, ketogenesis, proteolysis and
peripheral lipolysis were suppressed during euglycemic
hyperinsulinemia. This could be seen in the decreased arterial
concentration levels of precursors of these pathways, such as
multiple amino acids (including branched chain amino acids) and
FFAs, as well as of markers such as a- and b-hydroxybutyric
acids. Notably, a-hydroxybutyric acid has been considered as an
early marker for both insulin resistance and impaired glucose
regulation32.
A tracer study of NAFLD patients and controls suggest that
NAFLD is associated with increased TCA cycle, GNG and
lipolysis in the liver7. Our study conﬁrms that higher liver fat is
associated with more active TCA cycle metabolism. However, we
found in two independent approaches (ﬂux- and gene expression-
based analysis) that GNG from lactate is in fact decreased with
high liver fat at the expense of increased glyceroneogenesis.
Instead, patients with higher liver fat had higher rates of lipolysis
and GNG from glycerol. These differences were not due to obesity
itself as all patients were morbidly obese. Understandably, we
were not able to obtain liver biopsies from lean healthy subjects as
such would be unethical. The patients who participated in the
catheterization study were all patients who had been referred to
the hepatologist for a liver biopsy because of suspected NASH.
These patients were signiﬁcantly less obese than the patients in
the transcriptomics study. This is a limitation of the present
study.
Together, our ﬁndings indicate that in NAFLD glycerol is being
utilized as a preferential substrate for GNG instead of lactic acid.
In support of this hypothesis, 3-glycerolphosphate, an inter-
mediate of lipolysis, as well as multiple FFAs were positively
correlated with liver fat in the basal state. Furthermore, GSMM
analysis utilizing the metabolite ﬂux data as constraints showed
that reactions of glycerol kinase and glycerol-3-phosphate
acyltransferase, two of the key enzymes for glyceroneogenesis
and triglyceride synthesis, are strongly associated with liver fat
deposition. In support of our observation of the increased activity
of glycerol kinase, its protein abundance was found to be
signiﬁcantly increased in animal models with fatty liver33.
Moreover, a deﬁciency of mitochondrial glycerol-3-phosphate
acyltransferase results in reduced body weight and liver
triacylglycerol content and altered glycerolipid fatty acid
composition34, whereas overexpression of this enzyme results in
hepatic steatosis35.
Large differences were observed in the metabolic adaptability
scores when comparing NAFLD patients and healthy controls,
implying that NAFLD is characterized by reduced metabolic
adaptability at a network level. In other words, maintaining its
normal functioning requires a burden of post-transcriptional
regulation to increase as NAFLD progresses. This is consistent
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with our ﬁnding that NAFLD is associated with increased
opposite metabolic processes such as glyceroneogenesis and GNG
from glycerol, which may together contribute to the glycemic
control. Such a ﬁne balance of metabolic processes is broken
down in type 2 diabetes, where the GNG from lactate is markedly
increased. According to our model, high liver fat markedly
hampers the ability of the liver to adaptively regulate metabolism
to meet excessive demands on basic liver functions. Therefore,
individuals with NAFLD may be more vulnerable to various
metabolic stressors on the liver, such as hypercaloric diet or other
lifestyle factors contributing to positive energy balance. Taken
together, our data are consistent with NAFLD imposing a burden
on hepatic intermediary metabolism and suggest that speciﬁc
dietary regimes or therapies releasing pressure on the metabolic
switch observed in our study may ameliorate disease progression
in patients with NAFLD.
In summary, our study clearly shows that the increasing fat
load has a systemic effect on liver metabolic networks such as
reduced metabolic adaptability as well as induces mitochondrial
metabolism, glyceroneogenesis and a switch from lactate to
glycerol as substrate for GNG. The increasing metabolic stress
and loss of metabolic adaptability may together contribute to the
vicious pathogenic cycle leading to the co-morbidities of NAFLD
including development of type 2 diabetes.
Methods
Subjects in transcriptomics study. Clinical characteristics of the study groups are
shown in Supplementary Table 1. The subjects represented low and high extremes
of liver fat content of a group of previously described subjects undergoing
laparoscopic gastric bypass surgery or who were referred to the gastroenterologist
because of elevated liver function tests, and from patients whose remaining liver
samples sufﬁcient amounts of high-quality RNA could be prepared36. In brief,
these patients fulﬁlled the following inclusion and exclusion criteria: (i) age 18–60
years; (ii) alcohol consumption less than 2 drinks/day and (iii) no evidence of
hepatitis B or C, thyroid dysfunction, autoimmune hepatitis (smooth muscle and
antinuclear antibodies), primary biliary cirrhosis (antimitochondrial antibodies),
primary sclerosing cholangitis, a1-antitrypsin deﬁciency, use of hepatotoxic
medications or herbal products, or use of medications known to be associated with
steatohepatitis. Liver histology was analysed by an experienced liver pathologist in
a blinded manner as proposed by Brunt et al.37. Fat content of the liver biopsy
specimens was evaluated as % hepatocytes with macroscopic steatosis.
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The nature and potential risks of the study were explained to all subjects before
obtaining their written, informed consent. The study was carried out in accordance
with the principles of the Declaration of Helsinki. The protocol was approved by
the ethics committee of the Helsinki University Central Hospital.
Subjects in metabolomics study. Characteristics of the study subjects are shown
in Supplementary Table 2. All subjects were recruited among subjects referred to a
gastroenterologist because of elevated liver function tests based on the following
inclusion criteria: (i) age 18–75 years; (ii) no known acute or chronic disease except
for obesity based on history, physical examination and standard laboratory tests
(blood counts, serum creatinine, thyroid-stimulating hormone and electrolyte
concentrations) and ECG; (iii) alcohol abuse. The following causes of liver diseases
were excluded: chronic hepatitis B or C, thyroid dysfunction, autoimmune
hepatitis (smooth muscle and anti-nuclear antibodies), primary biliary cirrhosis
(anti-mitochondrial antibodies), primary sclerosing cholangitis, use of hepatotoxic
medications or herbal products or use of medications known to be associated with
steatohepatitis. Three subjects were receiving medications for hypertension. The
nature and potential risks of the study were explained to all subjects before
obtaining their written informed consent. The study protocol was approved by the
ethics committee of the Karolinska Hospital (Stockholm, Sweden). For ethical and
technical reasons, it was not possible to perform a similar study in healthy
volunteers.
Design of the metabolomics study. The subjects were studied after an overnight
fast. Three intravenous cannulas were inserted as described earlier5. Shortly, the
ﬁrst was inserted in an antecubital vein for infusions of saline (ﬁrst 90min),
glucose, insulin and potassium-[2,2-2H2]palmitate, the second was inserted in a
contralateral arm and the third catheter was inserted percutaneously under local
anaesthesia into a femoral vein38,39. Hepatic blood ﬂow was measured using a
constant intravenous infusion of indocyanine green40. Plasma glucose was
maintained at 5mmol l 1 (90mg dl 1) until 240min using a variable rate
infusion of 20% glucose. Potassium-[2,2-2H2]palmitate bound to human albumin
was infused at a rate of 0.05 mmol kg 1min 1 starting at 30min to trace FFA and
triglyceride metabolism in vivo. Hepatic blood ﬂow was measured at 90, 100, 110,
120, 200, 220, 240min. During the saline and insulin infusion, arterialized and
hepatic vein plasma samples were taken at 10–60min intervals.
The fat content of the liver biopsy specimens (% of hepatocytes with
macrovesicular steatosis) was determined by an experienced liver pathologist in a
blinded manner. The % of macrovesicular steatosis was used as the liver fat %. The
clinical parameters shown in Supplementary Table 2 were reported previously5.
In vivo study of gluconeogenic pathways. In another study conducted in 14
nondiabetic and 24 lean and 19 obese type 2 diabetic subjects28, liver fat content
was measured by magnetic resonance spectroscopy. We measured endogenous
(hepatic) glucose production (by 3H-glucose infusion) and the contribution of
GNG (by 2H2O ingestion) in the basal state and during 240 pmolm 2min 1
euglycemic-hyperinsulinemic clamp. Percent contribution of GNG to endogenous
(hepatic) glucose production (GNGtot) was quantiﬁed by the ratio of enrichments
of deuterium bound at Carbon 5 and at Carbon 2 of glucose molecule41; GNGpyr,
that is, from lactate/pyruvate, as the ratio of enrichments of deuterium bound at
Carbon 6 and at Carbon 2 (ref. 42); and GNGgly, that is, from glycerol, as the
difference between GNGtot and GNGpyr.
Transcriptomic analysis of liver biopsies. The transcriptomic analysis was
performed as in the earlier study at the DNA Sequencing and Genomics laboratory
at the University of Helsinki (Helsinki, Finland)43. In short, microarray analysis
was done using Agilent Whole Human Genome Microarray Kit, 4x44K chips
(Agilent catalogue # G4112F). Image analysis to compute the intensity values from
the TIFF ﬁles was done using GenePix Pro 6.0 software. The background was
estimated using local features, and bad spots were ﬂagged manually.
The individual channel intensities were read into R/Bioconductor44 and custom
spot quality weights were assigned. The intensity data are then processed with
quantile normalization method45. The preprocessing was performed using limma
package46 of R/Bioconductor.
Metabolomic analysis. Metabolomic analysis was performed at VTT Technical
Research Centre of Finland (Espoo, Finland).
Global analysis of polar metabolites. Metabolites were measured by the
established analytical platform based on two-dimensional gas chromatography
coupled to time-of-ﬂight mass spectrometry (GCGC-TOFMS)25. Each serum
sample (20 ml) was spiked with internal standard (20 ml labelled palmitic acid,
c¼ 258mg l 1) and the mixture was then extracted with 400ml of methanol. After
centrifugation, the supernatant was evaporated to dryness and the original
metabolites were then converted into their methoxime and trimethylsilyl
derivative(s) by two-step derivatization. First, 25 ml methoxamine reagent was
added to the residue and the mixture was incubated for 60min at 45 C. Next, 25 ml
N-methyl-N-(trimethylsilyl) triﬂuoroacetamide was added and the mixture was
incubated for 60min at 45 C. Finally, retention index (RI) standard mixture
(n-alkanes) in hexane was added to the mixture.
For the analysis, a Leco Pegasus 4D GCGC-TOFMS instrument (Leco Corp.)
equipped with a cryogenic modulator was used. The GC part of the instrument was
an Agilent 6890 gas chromatograph (Agilent Technologies), equipped with
split/splitless injector. The ﬁrst-dimension chromatographic column was a 10-m
RTX-5 capillary column with an internal diameter of 0.18mm and a stationary-
phase ﬁlm thickness of 0.20 mm, and the second-dimension chromatographic
column was a 1.5-m BPX-50 capillary column with an internal diameter of 100 mm
and a ﬁlm thickness of 0.1 mm. A diphenyltetramethyldisilazane deactivated
retention gap (3m 0.53mm i.d.) was used in the front of the ﬁrst column.
High-purity helium was used as the carrier gas at a constant pressure mode
(39.6 psig). A 5-s separation time was used in the second dimension. The mass
spectra were recorded by electron ionization at 70 eV in the m/z range of
45–700 a.m.u. with 100 spectra s 1. Split injection (1 ml, split ratio 1:20) at 260 C
was used. The temperature programme was as follows: the ﬁrst-dimension column
oven ramp began at 50 C with a 1-min hold after which the temperature was
programmed to 295 C at a rate of 10 Cmin 1 and then held at this temperature
for 3min. The second-dimension column temperature was maintained 20 C
higher than the corresponding ﬁrst-dimension column. The programming rate and
hold times were the same for the two columns.
The original GCGC-TOFMS data included retention times, RIs, spectral
information, possible identiﬁcation, spectral similarity value (S¼ 0–1,000) and
peak response data. The linear RIs were calculated based on the retention times of
the compounds and the retention times of the RI standards (n-alkanes). The data
were transferred into an in-house developed programme Guineu25. The alignment
of the data was done based on the two retention times and spectra. After
alignment of the GCGC-TOFMS data, two ﬁltration criteria were used for
positive identiﬁcation: (i) spectral match o850 and (ii) the RIexp-RIlito25 or
RIexp-RIstd_expo25, in which RIexp is the experimental RI for a compound and
RIlit is the literature value for the identiﬁed compound and RIstd_exp is the
experimental RI value for a standard compound. Compounds not fulﬁlling the
criteria were renamed to unknowns and were subjected to further identiﬁcation.
The identiﬁcation was based on the spectral search from NIST library or the
in-house collected library and the RIs. The compounds for which no spectral match
was found by the two libraries, GOLM database (http://gmd.mpimp-golm.mpg.de)
was utilized. The database was also used for functional group prediction of the
metabolites.
Calibration curves (six points, c¼ 15–2,000 ng, cholesterol c¼ 170–6,000 ng)
were constructed for the following compounds: pyruvic acid, alanine,
3-hydroxybutyric acid, valine, leucine, isoleucine, proline, glycine, succinic
acid, fumaric acid, serine, threonine, malic acid, methionine, aspartic acid,
alpha-ketoglutaric acid, phenylalanine, glutamic acid, ornithine, citric acid,
tyrosine, palmitic acid, linoleic acid, oleic acid, stearic acid, arachidonic acid and
cholesterol.
Quality control of the method showed that the day-to-day repeatability of
control serum samples, and the relative standard deviation (RSD) values for
quantiﬁed compounds (amino acids and carboxylic acids) was on average below
10%, ranging from 3 to 17%. The repeatability was also studied for the same
control serum samples using peak areas of the semiquantiﬁed compounds, and
including all major peaks in the investigation (220 peaks). The average RSD for
peak areas, utilizing total ion current trace, was below 24%. The internal standards
added to all serum samples in the study had an average RSD under 10%.
Analysis of bile acids. Glycolithocholic acid (GLCA) and glycoursodeoxycholic
acid (GUDCA) were obtained from Calbiochem, glycodeoxycholic acid (GDCA)
and ursodeoxycholic acid (UDGA) from Fluka, cholic acid (CA), deoxycholic acid
(DCA), glycocholic acid (GCA), glycochenodeoxycholic acid (GCDCA), lithocholic
acid (LCA), taurocholic acid (TCA), taurochenodeoxycholic acid (TCDCA),
taurodeoxycholic acid (TDCA), taurolithocholic acid (TLCA) and
tauroursodeoxycholic acid (TUDCA) were from Sigma-Aldrich and a-muricholic
acid (aMCA), bMCA, oMCA, TaMCA, TbMCA and taurohyodeoxycholic acid
(THDCA) from Steraloids. Internal standards, CA-d4, LCA-d4, UDCA-d4,
CDCA-d4, DCA-d4, GCA-d4, GLCA-d4, GUDCA-d4, GCDCA-d4 and GDCA-d4,
were obtained from Qmx laboratories except TCA-d4 was synthesized in our
laboratory.
Internal standards (20 ml of standard mixture; 2 p.p.m. for TCA-d4, 0.2 p.p.m.
for glycine conjugates, 2 p.p.m. for intact bile acids, respectively) and 20 ml of 1mM
norvaline was added to 20 ml sample and mixture was vortexed for 30 s. 60 ml of
acetonitrile was added to precipitate proteins. After vortexing for 60 s, samples
were centrifuged at 13,200 r.p.m. for 5min. 90 ml of sample was evaporated with
nitrogen and reconstituted to 20 ml of methanol, and diluted with 20 ml of water.
Analysis was performed on an Acquity Ultra-Performance Liquid
Chromatography system, Waters, and Waters Xevo TQ MS. Chromatography was
performed using an Acquity HSS T3 (2.1 150mm2, 1.7 mm) column, Waters,
kept at 30 C. Injection volume was 2.0 ml. Separation was performed using (i)
gradient elution with 10mM formic acid in water (v/v) and (ii) with 10mM formic
acid in acetonitrile at a ﬂow rate of 0.4mlmin 1 with a gradient elution mode.
Mass spectrometry was performed in negative ion electro spray mode. Cone voltage
was 70V and collision energy 2 eV for intact bile acids, 58 V and 46 eV for glycine
conjugates and 90V and 63 eV for taurine conjugates, respectively. The capillary
voltage was 2.4 kV, desolvation temperature was 650 C and source temperature
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was 150 C. The cone gas ﬂow was 30 l h 1, desolvation gas was 1,000 l h 1 and
collision gas was 0.15mlmin 1. Analytes were detected using selected reaction
monitor using dwell times of 100–250ms.
Human model modiﬁcation. The modiﬁcation of the human GSMM10 includes
the addition of a biomass reaction and two reactions that enable the formation and
degradation of glycogen. These reactions are: (i) the demand of glycogen and (ii)
the demand of apo-glycogenin protein, the primer for glycogen synthesis. The
modiﬁed model in a MATLAB format is accessible through a supplementary
website http://www.cs.tau.ac.il/Blivnatje/NAFLD_model.mat.
Expression-based GSMM analysis and metabolic functionality assessment.
Gene expression proﬁles were analysed via GSMM to generate metabolic proﬁles
for each patient. These proﬁles aim to capture the metabolic phenotype by
integrating the gene expression proﬁles with a GSMM21. The metabolic proﬁles
include an activity and an adaptability score for 22 key liver metabolic functions as
deﬁned by Gille et al.20. A metabolic function is deﬁned by a speciﬁc reaction—
usually a reaction that generates the end-product of the metabolic function—and a
set of constraints. For example, for the process of GNG from lactate, the constraints
are deﬁned such that lactate is the only carbon source that can be used to produce
glucose, and the end-reaction is the one that produces glucose.
Given the gene expression proﬁle of sample j the activity score of a metabolic
function i is computed as follows. Let ri and Ci be the reaction and set of constrains
that deﬁne metabolic function i. Let Ai be the maximal ﬂux through ri when the
model is constrained according to Ci. Let Aij be the maximal ﬂux through ri when
the model is constrained according to Ci and according to the gene expression of
sample j. The gene expression constraints are imposed by applying iMAT19,47. The
activity score of a metabolic function i in sample j is then the ration Aij/Ai. The
activity sore, hence, denotes the ability of the model to activate the metabolic
function while maintaining the optimal consistency to the gene expression.
The adaptability score of a metabolic function i in sample j is computed by
employing MPA48. Let Faji be the maximal ﬁt to the gene expression under the Ci
constraints when enforcing ri to be active. rj is activated by setting its lower bound
to be 0.5 of its maximal ﬂux rate in the original—unconstrained—model. Let Fji be
the maximal ﬁt to the expression under the Ci constraints. The ration Faji/Fji is the
adaptability score of the metabolic function i in a sample j. High adaptive
functionality values indicate that the function studied can be carried out with
relatively little deviation from the given expression state and vice versa.
The MATLAB implementation of the metabolic functionality assessment is
accessible through a supplementary website http://www.cs.tau.ac.il/Blivnatje/
MPA.zip.
Flux-based GSMM analysis. The ﬂux-based analysis was conducted in a
two-staged manner by utilizing a modiﬁed version of the human GSMM10.
Primarily, given a set of ﬂuxes, a feasible ﬂux distribution that optimally ﬁts the ﬂux
measurements and satisﬁes stoichiometric and thermodynamic constraints is
found. This is done by solving a quadratic programming (QP) problem in which
the Euclidian distance between the measurements and the resulting predicted ﬂux
distribution is minimized. This minimal distance is termed the consistency score,
as it denotes the consistency between the model and the measurements. Most
frequently, because of inaccuracies in the model as well as noise in the data, there is
not a feasible ﬂux solution that precisely ﬁts the measured ﬂuxes. Therefore, the
consistency score is greater than zero. The ﬂux distribution that is found via QP is
utilized to constrain the model according to the ﬂux measurements. Next, Flux
Variability Analysis49 is applied to compute the upper and lower bounds of all the
reactions in the model, whereas ﬁxing the ﬂux through the measured reactions to
the values found using QP in the ﬁrst step.
Based on the ﬂux intervals computed above the reactions are divided into active
and inactive reactions. A reaction is considered active if it can carry a ﬂux with an
absolute value greater than 0.001. Metabolic pathway activity is deduced by
performing hyper-geometric enrichment tested based on the activity state of the
reactions, identifying which pathways are enriched with active or inactive reactions.
To identify metabolic reactions that are signiﬁcantly correlated with fat-level
pre- and post-insulin Spearman correlation was computed. Subsequently, an
empirical P-value was computed by randomly shufﬂing the labels of the fat levels
and computing the Spearman P-value for each reaction. The correction for
multiple hypothesis testing was performed via false discovery rate control, with a
rate of 0.1.
Model consistency validation. To validate the ﬁt between the metabolic model10
and the ﬂux measurements, we utilized two data sets of 21 mean ﬂux measured
pre- and post-insulin administration. Their consistency scores were computed, and
the statistical signiﬁcance of these scores was evaluated as follows: 1,000 random
sets of measurements, within the scale of the original ﬂux measurements, were
generated. For each one of these sets the consistency score was computed, to obtain
the empirical P-value of the consistency scores over the real data sets.
Metabolic functionality-based classiﬁcation. The metabolic functionality scores,
generated based on the gene expression measurements, were utilized to classify the
patients as having a high or low liver fat amount. The classiﬁcation was performed
via the SVM library (LIBSVM)50. The samples were randomly divided into test and
train sets 100 times. Each time two-third of the samples are used for training and
the remaining one-third for testing. The classiﬁcation performances were measured
in a standard manner based on the AUCs of the receiver operating curves obtained.
The statistical signiﬁcance of the AUCs obtained was computed via permutation
tests, performing the classiﬁcation task 1,000 times with shufﬂed labels.
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